Phase III trial shows personalized mRNA therapy plus pembrolizumab cuts melanoma recurrence risk by 42%
The INTerpath‑001 Phase III study enrolled 1,137 adults with resected stage IIB‑IV cutaneous melanoma and randomly assigned them 2:1 to intismeran autogene plus pembrolizumab or placebo plus pembrolizumab. At a median 24.6‑month follow‑up the combination reduced the risk of recurrence or death by 42% (hazard ratio 0.58) and improved 24‑month recurrence‑free survival to 82.2% versus 70.0%. Distant metastasis‑free survival also improved, with a 38% risk reduction (hazard ratio 0.62) and 24‑month rates of 88.5% versus 80.2%. The data were leaked two days before the scheduled ESMO presentation, triggering a sharp sell‑off in Moderna shares (≈‑25%) and a smaller decline in Merck shares (≈‑1%).
Why it matters
The trial establishes a new adjuvant standard for high‑risk melanoma, which could drive future sales for Moderna and Merck’s mRNA oncology pipelines. The premature data leak caused immediate market volatility, wiping roughly $24 bn from Moderna’s market value.
Key facts
- 1The trial enrolled 1,137 patients, with 757 receiving intismeran plus pembrolizumab and 380 receiving placebo plus pembrolizumab. emjreviews.com
- 2Median follow‑up was 24.6 months. emjreviews.com
- 3Hazard ratio for recurrence or death was 0.58, a 42% risk reduction. emjreviews.com
- 424‑month recurrence‑free survival was 82.2% with the combination versus 70.0% with placebo. emjreviews.com
- 5Hazard ratio for distant metastasis or death was 0.62, a 38% risk reduction. onclive.com
- 624‑month distant metastasis‑free survival was 88.5% versus 80.2%. onclive.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.